ALVO — Alvotech

Nasdaq · Health Care · Biotechnology · CIK 1898416 ·
Last close
$3.28
Market Cap
$1.11B
52W High
$4.59
52W Low
$2.94
ADV30
1,001,864
Next earnings
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 105,865,000 59,778,000 9,674,000 1,030,000 1,421,168,000 63,832,000 1,703,480,000
Dec 2025 166,573,000 105,293,000 48,255,000 -108,547,000 1,487,099,000 172,359,000 1,771,586,000
Sep 2025 113,744,000 78,738,000 1,313,000 -5,252,000 1,409,178,000 42,848,000 1,585,941,000
Jun 2025 173,239,000 99,414,000 18,057,000 32,038,000 1,392,754,000 151,452,000 1,566,082,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-50,197,000
Investing CF
$-104,215,000
Financing CF
$270,832,000
CapEx
$-96,129,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.35
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,409,790,000
Inventory
$220,054,000
Receivables
$153,786,000
ST Investments
EBIT TTM
$273,218,000
Pretax Income TTM
$136,348,000
Interest Exp TTM
$136,870,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$562,043,008
EBITDA
$104,241,000
Free Cash Flow
$-92,554,376
Enterprise Value
$2,429,797,632
Total Cash
$63,832,000
Total Debt
$1,457,281,024
Shares Out
338,219,831
Trailing EPS
$-0.29
Book Value
$-0.90
ROE
ROA
3.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 586,321,000 78,207,000 27,919,000 1,487,099,000 1,771,586,000 -50,197,000
Dec 2024 489,682,000 69,644,000 -231,864,000 1,221,400,000 1,634,171,000 -236,843,000
Dec 2023 91,434,000 -354,860,000 -551,731,000 950,090,000 1,882,583,000 -312,185,000
Dec 2022 83,029,000 -346,442,000 -513,580,000 828,443,000 1,392,859,000 -312,389,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.23

Peers — same industry

TickerNameMarket CapLastDaily %
CGEM Cullinan Therapeutics, Inc. $1.11B $18.13
SANA Sana Biotechnology, Inc. $1.07B $3.85
VOR Vor Biopharma Inc. $1.04B $19.14
SLDB Solid Biosciences Inc. $1.03B $10.42
MGTX MeiraGTx Holdings plc $1.24B $13.39

News headlines (Yahoo Finance, 1h cache)

Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering
2026-07-02 20:11 · Yahoo
Alvotech’s US$240 Million Capital Boost Might Change The Case For Investing In Alvotech (ALVO)
2026-07-02 10:09 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed Chair Warsh's International Debut
2026-07-01 12:39 · Yahoo
Alvotech further strengthens liquidity by securing term loan facility of $75 million
2026-07-01 08:00 · Yahoo
Alvotech (ALVO): 10 Penny Stocks With Explosive Growth Potential
2026-06-20 17:27 · Yahoo
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
2026-06-18 09:51 · Yahoo
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
2026-06-18 08:00 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Fed Policy Meeting
2026-06-16 12:34 · Yahoo
Alvotech Prices Share Offering, Private Placement
2026-06-16 08:11 · Yahoo
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
2026-06-16 03:59 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.